- Home
- BLND vs PROK Comparison
BLND vs PROK Comparison
Compare BLND & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLND | PROK |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.6M | 416.6M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BLND | PROK |
|---|---|---|
| Price | $1.77 | $1.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $4.13 | ★ $7.40 |
| AVG Volume (30 Days) | ★ 2.1M | 1.3M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.33 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $123,585,000.00 | $893,000.00 |
| Revenue This Year | $12.62 | N/A |
| Revenue Next Year | $14.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $1.18 | $1.45 |
| 52 Week High | $4.49 | $3.55 |
Technical Indicators
Market Signals| Indicator | BLND | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 51.17 | 40.13 |
| Support Level | $1.58 | N/A |
| Resistance Level | $1.87 | $2.59 |
| Average True Range (ATR) | 0.11 | 0.09 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 42.54 | 17.65 |
Price Performance
Historical ComparisonAbout BLND Blend Labs Inc.
Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segment is Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience. The key revenue for the company is generated from the Blend Platform segment. Company has it's assets in united states, India and Mexico regions.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.